Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571
TO THE EDITOR Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder arising from a neoplastic transformation in a stem cell capable of differentiating into myeloid, erythroid, megakaryocytic, B-lymphoid and occasionally T-lymphoid cell lineages. The hallmark of the disease is the Philadelphia (Ph) chromosome formed from a reciprocal translocation t(9;22)(q34;q11), found in up to 95% of the cases. The molecular consequence of this translocation is the creation of the BCR-ABL fusion gene which encodes the P210 BCR-ABL hybrid protein. This protein is a constitutively active cytoplasmic tyrosine kinase. Two lines of evidence support the concept that BCR-ABL plays a central role in the pathogenesis of CML: (1) retroviral transduction experiments in which P210
BCR-ABL expressed in murine bone marrow cells resulted in a myeloproliferative disorder resembling CMI; 1 and (2) a novel agent, STI571 (Glivec or Imatinab Mesylate), a tyrosine kinase inhibitor with relative selectivity for inhibiting the BCR-ABL fusion protein in mice and the growth of human Ph-positive, BCR-ABL positive cells in vitro and in vivo.
2 STI571 is a synthetic compound that was rationally designed to compete with ATP for the binding site of tyrosine kinases. STI571 inhibition of the Ph-positive, BCR-ABL fusion positive cells represents a major therapeutic advance in the management of CML. Since clinical trials with STI571 started in 1999, over 5000 patients have been treated with it.
Here we report a patient who was enrolled on multinational trial of STI571 in interferon-resistant patients and 3 months later developed triploidy, as well as amplification of the BCR-ABL gene. The patient was a 60-year-old woman who was diagnosed with Ph-positive CML in 1995. At that time, her white cell count (WBC) was 25 000/mm 3 with hemoglobin of 12.7 g/dl, a hematocrit of 38% and platelets of 300 000/mm 3 . Initially she was treated with interferon alpha for 1 year. Although she remained stable during that time and her WBC counts decreased, she did not show a cytogenetic response. In 1997, Ara-C was added to her treatment regimen with no significant response. In June 2000, the patient was enrolled in an STI571 clinical trial (dose of 400 mg/day) when she showed evidence of disease progression manifested by an enlarging spleen, WBC count of 51 000/mm 3 , anemia and thrombocytopenia. A bone marrow biopsy and aspirate performed prior to enrollment in the study were consistent with chronic phase CML. Cytogenetics studies showed 46,XX,t(9;22)(q34;q11.2). Interphase FISH analysis with BCR-ABL ES (extra sensitive) probe (Vysis, Downers Grove, IL, USA) showed that 91% of her cells were positive for the BCR-ABL fusion gene.
Despite STI571 treatment and decrease of WBC count to 3400/mm 3 over 3 months, the patient's condition worsened manifesting increased anemia and thrombocytopenia which required frequent transfusions. In addition, more than 10% of her circulating WBC were blasts. In October 2000, at the time of her first interval follow-up while on STI571, cytogenetic analysis was performed on 32 bone marrow metaphases. It showed the modal karyotype 69-72,XXX, +1, +der(4)t(4;?)(q36;?), +6, −7, +8, +8, t(8;17)(q23;q22), t(9;22)(q34;q11. acentric fragments ( Figure 1 ). There were two copies of der(9) and no normal chromosome 9. Each cell had either four copies of the Ph chromosome or three copies of the Ph chromosome and one copy of ider (22) Figure  2 ). Metaphase FISH analysis confirmed the lack of normal chromosome 9 and 22. Further, metaphase FISH using chromosome painting probes confirmed pentasomy of chromosome 8, tetrasomy for chromosome 14, t(8;17) and the additional deleted chromosome 17. By the end of October 2000, the patient was hospitalized because of severe pneumonia complicated with sepsis and expired soon after hospitalization.
To our knowledge, this is the first report that describes homozygous Ph chromosome that developed at two different time points; at diagnosis and 3 months following induction of ST1571 therapy. The most likely explanation is that the second translocation t(9;22) and the amplification of each Ph chromosome were related to ST1571 treatment. It is possible however, that these genetic alterations are a manifestation of transformation of chronic phase CML into blast crisis; however, neither these findings nor the triploidy are characteristic of such an event. Blast crisis of CML may be myeloid or lymphoid. About 15-20% of patients in blast crisis retain the 46 Ph + cell population unchanged, whereas 80-85% show karyotypic evolution. The most common changes, gain of chromosomes 8, 19 and i(17q) frequently occur in combination with duplication of the Ph chromosome to produce modal chromosome numbers of 47-50. When patients have only a single new chromosome change, it most commonly, involves the gain of the second Ph, an i(17q), or +8, or +19 in descending order of frequency. Other rearrangements occur less frequently. The chromosome 22 homologue is almost always intact. To our knowledge, blast crisis characterized by a triploid range of chromosomes has not been reported. Triploidy in this patient, combined with pentasomy 8, is another unique aspect, and may represent either a rare cytogenetic evolution in blast crisis or it may be related to ST1571 treatment. One could speculate that cell resistance to ST1571 may be caused by deregulation of protein kinases genes involved in cell cycle checkpoints resulting in increased ploidy.
In ongoing phase I clinical trials, ST1571 showed significant activity in all phases of CML, as well as Ph chromosome-positive acute leukemias. 3, 4 At daily oral doses of 300 mg or more, a complete hematological response was achieved in 100% of the patients in chronic phase CML and cytogenetic responses were observed in 53% with complete cytogenetic remissions in 13%. Most of these responses are maintained with ongoing therapy. In patients with Ph-positive acute leukemias, relapses have been a major problem. This raises the possibility that later relapses will also be seen in chronic phase patients because of resistance to ST1571.
Experiments in mouse and human cell lines have shown that the most frequent mechanism of resistance to standard doses of ST1571 is amplification and overexpression of the BCR-ABL gene. 5 A partial bone marrow karyotype from two marrow cells (top and third row) at the first interval following ST1571 treatment. The top row shows three Ph chromosomes and one ider(22)t(9;22) resulting in five Ph chromosomes. The second row shows the same chromosomes after FISH studies confirming five copies of BCR-ABL fusion (yellow) and the residual ABL (red) signal on both der(9). The third row shows six copies of the Ph chromosome, two are in the form of ider(22)t(9;22). The same cell after FISH studies demonstrating six copies of the BCR-ABL fusion (yellow).
our findings, recent work demonstrated BCR-ABL amplification in three patients undergoing treatment with ST1571, one patient with ALL and two patients with advanced CML. 6 All three patients had relapsed leukemia after an initial response. Two of three patients developed in addition to the standard t(9;22), der(22)inv dup(22)(q11.2)t(9.22)(q34;q11.2). Essentially, both patients had duplicated and inverted Ph chromosome. As mentioned above, duplication of the Ph chromosome is one of the common cytogenetic manifestations in blast transformation. However, the presence of three or more Ph copies through a nondysjunction process is an unusual finding. All four patients had amplification of the Ph chromosome occurring with disease progression. Nevertheless, whatever the exact mechanism may be causing homozygous occurrence of t(9;22), multiple copies of the Ph chromosome, amplification of the BCR-ABL gene, and increased ploidy, early detection of these phenomena, particularly in the chronic phase of the disease, may be important in treatment modifications to overcome ST1571 resistance. 3 Moreover, an inguinal lymph node biopsy was performed. The patient underwent chemotherapy with CAG (cytarabine 10 mg/m 2 on days 1-14, aclarubicin 14 mg/m 2 on days 1-4, and G-CSF 200 g/m 2 on days 1-14). Blasts in the bone marrow aspiration and peripheral blood gradually decreased, and pancytopenia progressed in the patient's peripheral blood. However, swelling of the cervical, inguinal, and para-aortic lymph nodes has progressed 9 months after diagnosis. The patient ultimately died of cerebral and pulmonary bleeding.
We reported a rare case of AML-M0 and progressive generalized lymphadenopathy constituted of granulocytic sarcoma. The initial cervical and second inguinal lymph node biopsy specimens were reviewed. These cells were negative for CD20, CD3, CD45RO, CD16, CD56, CD68, ␣-l antitrypsin, lysozyme, S-100 protein, and chloroacetate esterase. HTLV-I proviral monoclonal integration was negative. As shown in Figure 1 , the cells of the infiltrate had oval nuclei with stippled chromatin, occasional small nucleoli, and scanty cytoplasm. Conventional immunostaining with antibodies for myeloperoxidase revealed tumor cells to be negative. An amplified immunohistochemical method using the CSA system (Dako, Glostrup, Denmark) was performed with polyclonal antibody to MPO (diluted at 1:500). Detailed procedures of immunohistochemistry using the CSA system are described in the manufacturer's protocol. A few cells showed immunoreactivity for the MPO protein by catalyzed signal amplification immunohistochemistry methods (CSA system) (Figure 2a) . A negative control study with substitution of normal rabbit serum for the primary antibody showed no positive staining for MPO (Figure 2b ). In situ hybridization was then performed using catalyzed signal ampli-
Figure 1
Characteristics of a lymph node. Lymph node biopsy showing diffuse proliferation of medium-or large-sized cells with oval nuclei with stippled chromatin, occasional small nucleoli, and scanty cytoplasm (HE, × 400).
